Blis Technologies is heralding a major milestone with approval for its oral probiotic Blis K12 as a food ingredient in China.
The approval by the Chinese State Food and Drug Administration represented the end of a regulatory approval process that started in 2008.
It enables NZPR Group, which is the commercialisation partner of the Dunedin-based biotechnology company in China, to actively market Blis K12 lozenges and associated products through its distribution networks within the country.
The company was "extremely pleased" with the achievement and anticipated it would soon be assisting NZPR Group further, with sales and marketing in China, it said in a statement.
Blis K12 is a natural bacteria, promoted as a probiotic prevention of upper-airways infection, bacterial sore throats, tooth and gum disease and chronic bad breath.
Blis Technologies has also announced it will enter into a market development partnership with Canada-based Integra Medical, which will produce and sell products in eastern Europe.
Integra Medical has already successfully achieved regulatory approval for its first Blis K12-based product as a dietary supplement within Russia and has embarked on clinical trials to support its application for its products as an approved medicine in Russia.
